Patent ID: 11919966
Assignee: ABLYNX N.V.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 15:
16. The method according to claim 15, wherein said at least one immunoglobulin single variable domain essentially consists of 4 framework regions (FR1 to FR4, respectively) and 3 complementarity determining regions (CDR1 to CDR3, respectively), in which:
(i) CDR1 is chosen from the group consisting of:
(a) SEQ ID NOs: 73-75; and
(b) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 73; and/or

(ii) CDR2 is chosen from the group consisting of:
(c) SEQ ID NOs: 90-98; and
(d) amino acid sequences that have 4, 3, 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 90; and/or

(iii) CDR3 is chosen from the group consisting of:
(e) SEQ ID NOs: 118-119, 123 and 282-284; and
(f) amino acid sequences that have 2, or 1 amino acid(s) difference with the amino acid sequence of SEQ ID NO: 118.